These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 23181541)
1. Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review. Omazzi B; Prada A; Borroni G; Sacrini F Hepatol Res; 2012 Dec; 42(12):1248-51. PubMed ID: 23181541 [TBL] [Abstract][Full Text] [Related]
2. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C. Taliani G; Biliotti E; Capanni M; Tozzi A; Bresci S; Pimpinelli N J Chemother; 2005 Apr; 17(2):212-4. PubMed ID: 15920908 [TBL] [Abstract][Full Text] [Related]
3. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Kartal ED; Alpat SN; Ozgunes I; Usluer G Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):817-20. PubMed ID: 17700271 [TBL] [Abstract][Full Text] [Related]
4. Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report. Gamal N; Brodosi L; Misciali C; Patrizi A; Vukatana G; Malavolta N; Bernardi M; Andreone P Ann Hepatol; 2014; 13(2):293-6. PubMed ID: 24558223 [TBL] [Abstract][Full Text] [Related]
5. Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report. Verma P; Dayal S; Jain VK; Amrani A J Chemother; 2017 Dec; 29(6):380-382. PubMed ID: 27741937 [TBL] [Abstract][Full Text] [Related]
6. Hirschsprung's disease associated with alopecia universalis congenita: a case report. Malik S; Singhal M; Jadhav SS; Korday CS; Nayak CS J Med Case Rep; 2016 Sep; 10(1):250. PubMed ID: 27633379 [TBL] [Abstract][Full Text] [Related]
7. Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy. Turker K; Tas B; Ozkaya M; Tas E; Caglar A; Tetikkurt US Hepat Mon; 2015 Mar; 15(3):e24804. PubMed ID: 25821474 [TBL] [Abstract][Full Text] [Related]
9. Hepatitis C treatment and alopecia totalis. Goh C J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S59-60. PubMed ID: 24326562 [TBL] [Abstract][Full Text] [Related]
10. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C. Baker RD; Dee D; Baker SS J Clin Gastroenterol; 2007 Jan; 41(1):111-4. PubMed ID: 17198073 [TBL] [Abstract][Full Text] [Related]
11. Alopecia universalis associated with cutaneous T cell lymphoma. Miteva M; El Shabrawi-Caelen L; Fink-Puches R; Beham-Schmid C; Romanelli P; Kerdel F; Tosti A Dermatology; 2014; 229(2):65-9. PubMed ID: 24821490 [TBL] [Abstract][Full Text] [Related]
12. Diffuse hypertrichosis in the course of hepatitis C treatment by IFN-alpha and ribavirin. Misery L J Interferon Cytokine Res; 2002 Aug; 22(8):881-2. PubMed ID: 12396727 [TBL] [Abstract][Full Text] [Related]
13. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin. Demirturk N; Aykin N; Demirdal T; Cevik F Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483 [No Abstract] [Full Text] [Related]
14. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C. Li Z; Zhang Y; An J; Feng Y; Deng H; Xiao S; Ji F J Clin Virol; 2014 Jul; 60(3):190-5. PubMed ID: 24830933 [TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877 [TBL] [Abstract][Full Text] [Related]
16. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule]. Horváth G; Tolvaj G; Halász T; Stotz G Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672 [TBL] [Abstract][Full Text] [Related]
17. A Case Series and Literature Review of Telogen Effluvium and Alopecia Universalis after the Administration of a Heterologous COVID-19 Vaccine Scheme. Hernández Arroyo J; Izquierdo-Condoy JS; Ortiz-Prado E Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851320 [TBL] [Abstract][Full Text] [Related]
18. [Antiviral/immunomodulatory combination therapy: pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection]. Delić D; Mitrović N; Popović N; Urošević A; Pešiċ I; Simonoviċ J Srp Arh Celok Lek; 2012; 140(9-10):612-8. PubMed ID: 23289278 [TBL] [Abstract][Full Text] [Related]
19. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies. Fabrizi F; Dixit V; Messa P; Martin P J Viral Hepat; 2014 Oct; 21(10):681-9. PubMed ID: 25040244 [TBL] [Abstract][Full Text] [Related]
20. Trichotillomania: Bizzare Patern of Hair Loss at 11-Year-old Girl. Zímová J; Zímová P Acta Dermatovenerol Croat; 2016 Jun; 24(2):150-3. PubMed ID: 27477178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]